USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: SENTIEN BIOTECHNOLOGIES, INC.
Address: 196 Boston Ave
Medford, MA 02155
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,314,291.00 4
SBIR Phase II $773,285.00 1

Award List:

A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Biju Parekkadan
Award Amount: $565,011.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase I project is to create technical protocols for the reproducible operation of our proprietary cell-based device for the treatment of acute renal failure. The project specific aims are: (1) To identify active therapeutic secreted… More

SBIR Phase I:Assembly and Storage of Cell-Derived Drug Delivery Devices

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: NSF
Principal Investigator: Biju Parekkadan, DPhil
Award Amount: $150,000.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes the development of a stem cell-based extracorporeal device that can offer unparalleled support to 200,000+ patients undergoing severe acute kidney injury annually. The device delivers cell-derived secretions of anti-inflammatory… More

Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Arno W. Tilles – 617-724-2953
Award Amount: $773,285.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the treatment of acute renal failure (ARF) in dogs. The project specific aims are: (1) Biomarker-guided… More

Blood Purification for Organ Failure

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: DOD
Principal Investigator: Arno Tilles, Chief Technology Officer – (781) 361-9031
Award Amount: $99,974.00
Abstract:
Sentien Biotechnologies is developing cellular devices for the treatment of acute organ failure, including polytrauma-induced multiple organ dysfunction syndrome (MODS). Our flagship product, the Sentinel, is a dialyzer with mesenchymal stem cells (MSCs) seeded in the extracapillary space, designed… More

Cellular Device for the Treatment of Acute Liver Failure

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arno W. Tilles – 617-724-2953
Award Amount: $499,306.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions to provide combined anti-inflammatory and regenerativesupport. The project specific aims are: (1)… More